Ofatumumab (O) in Combination With Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating With Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma
Description: 

This open-label, single-arm, multi-center Phase II study evaluating efficacy, the safety, and tolerability of ofatumumab antibody in combination alternating doses of Hyper-CVAD and MA in previously untreated MCL administered at every 3 week intervals for six cycles followed by HDC-ASCT in eligible patients.

Study Number: 

I 201611

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01527149

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.